Back to top
more

DexCom (DXCM)

(Real Time Quote from BATS)

$75.93 USD

75.93
1,848,936

-0.62 (-0.81%)

Updated Sep 17, 2025 12:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

DexCom (DXCM) Q4 Earnings and Revenues Top Estimates

by Zacks Equity Research

DexCom (DXCM) delivered earnings and revenue surprises of 237.50% and 2.18%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Masimo and Saudi Arabia MOH Collaborate for CCHD Screening

by Zacks Equity Research

Studies have shown that Masimo's (MASI) SET pulse oximetry can improve CCHD screening, helping to save newborns.

Zacks Equity Research

Luminex Hurt By Segmental Sluggishness, Stiff Competition

by Zacks Equity Research

Luminex's (LMNX) dependence on its partners for revenue generation is a major problem.

Zacks Equity Research

DexCom (DXCM) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Here's Why Investors Should Buy CONMED (CNMD) Stock Now

by Zacks Equity Research

CONMED's (CNMD) guidance for 2019 buoys optimism in the stock.

Zacks Equity Research

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom (DXCM) expects to gain from strong demand for the G6 sensors. These sensors are likely to rake in huge profits during the fourth quarter of 2018.

Zacks Equity Research

Ecolab (ECL) Reports Preliminary Q4 Results, Issues Guidance

by Zacks Equity Research

Ecolab (ECL) plans to spin off Upstream Energy sub-unit as a stand-alone publicly-traded company by mid-2020.

Zacks Equity Research

Can TruBridge Fuel Computer Programs' (CPSI) Q4 Earnings?

by Zacks Equity Research

Computer Programs (CPSI) is likely to gain from TruBridge platform in fourth-quarter 2018.

Zacks Equity Research

BD Gains From Solid Global Base, Headwinds Anticipated

by Zacks Equity Research

Becton, Dickinson's (BDX) solid geographical expansion encourages; raw material pricing pressure raises concern.

Zacks Equity Research

HealthEquity's (HQY) Preliminary Q4 Results Cheer Investors

by Zacks Equity Research

HealthEquity's (HQY) solid guidance for fiscal 2019 favors stock.

Zacks Equity Research

3 Medical Instruments Stocks Likely to Beat Estimates in Q4

by Zacks Equity Research

Medical Instruments companies are likely to gain from strong performance in emerging economies and modernization of 510 (k)-clearance pathway by the FDA in Q4.

Zacks Equity Research

Will Diagnostics Business Ail LabCorp (LH) in Q4 Earnings?

by Zacks Equity Research

LabCorp (LH) is likely to gain traction from the company's collaboration with Walgreens.

Zacks Equity Research

Can Boston Scientific (BSX) Q4 Earnings Fuel Overall Growth?

by Zacks Equity Research

We are hopeful that Boston Scientific (BSX) will report a strong IC business globally in Q4, backed by an innovative portfolio and robust commercial teams.

Zacks Equity Research

Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?

by Zacks Equity Research

Myriad (MYGN) likely to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight, EndoPredict, BRACAnalysis CDx and Prolaris tests.

Zacks Equity Research

Cerner (CERN) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Cerner's (CERN) fourth-quarter 2018 results are likely to be hurt by year-over-year decline in bookings; Q4 guidance promising.

Zacks Equity Research

Can Zimmer Biomet (ZBH) Grow on Hip Business in Q4 Earnings?

by Zacks Equity Research

Within Hip business, we expect Zimmer Biomet (ZBH) to experience a strong uptick in the Asia-Pacific region.

Zacks Equity Research

Can CAG Growth Steadily Drive IDEXX (IDXX) in Q4 Earnings?

by Zacks Equity Research

IDEXX (IDXX) is expected to keep its momentum alive in Q4, banking on a strong global rise in Companion Animal Group Diagnostics' revenues.

Zacks Equity Research

Can BD Medical Drive Becton, Dickinson's (BDX) Q1 Earnings?

by Zacks Equity Research

Becton, Dickinson's (BDX) solid fiscal first-quarter preliminary results boost optimism in the stock.

Zacks Equity Research

Will Core Business Units Boost McKesson's (MCK) Q3 Earnings?

by Zacks Equity Research

McKesson (MCK) expects to gain from solid segmental performances in third-quarter fiscal 2019.

Zacks Equity Research

ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates

by Zacks Equity Research

ResMed (RMD) benefits from growth at CER across all geographies. However, device sales in France and Japan get affected.

Zacks Equity Research

AmerisourceBergen (ABC) Q1 Earnings: What's in the Cards?

by Zacks Equity Research

AmerisourceBergen's (ABC) first-quarter fiscal 2019 results are likely to gain from its core Pharmaceutical Distribution business unit.

Zacks Equity Research

What's in Store for Edwards Lifesciences' (EW) Q4 Earnings?

by Zacks Equity Research

Edwards Lifesciences (EW) expected to see consistent performance by Surgical Structural Heart and Critical Care segments in Q4.

Zacks Equity Research

Will Flagship Impella Drive ABIOMED's (ABMD) Q3 Earnings?

by Zacks Equity Research

ABIOMED (ABMD) is likely to gain from flagship Impella in third-quarter fiscal 2019; positive trends in the CHD markets buoy optimism.

Zacks Equity Research

NextGen's (NXGN) Q3 Earnings Beat Estimates, Bookings Up Y/Y

by Zacks Equity Research

NextGen (NXGN) delivers strong growth in software, hardware and other non-recurring revenues in Q3; strong fiscal 2019 view buoys optimism.

Zacks Equity Research

What's Setting the Tone for Hologic's (HOLX) Q1 Earnings?

by Zacks Equity Research

Strength in the Breast Health business, Panther system and international business is likely to boost Hologic's (HOLX) top line in Q1.